Additional value of B-type natriuretic peptide on discrimination of patients at risk for mortality after a non-ST-segment elevation acute coronary syndrome

European Heart Journal: Acute Cardiovascular Care

Volumn 3, Issue 2, 2014, Pages 132-140

  García Alvarez, Ana ^a   Regueiro, Ander ^a   Hernández, Jaime ^a   Kasa, Gizem ^a   Sitges, Marta ^a   Bosch, Xavier ^a   Heras, Magda ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

B type natriuretic peptide; mortality; non ST segment elevation acute coronary syndrome; prognosis; reclassification

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

ACUTE CORONARY SYNDROME; AGED; BLOOD; EVALUATION STUDY; FEMALE; HOSPITALIZATION; HUMAN; MALE; METABOLISM; MORTALITY; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA;

ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; FEMALE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; ROC CURVE;

EID: 84922252681     PISSN: 20488726     EISSN: 20488734     Source Type: Journal    
DOI: 10.1177/2048872614520753     Document Type: Article

References (41)

1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177–1189.
2. Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002; 23: 1190–1201.
3. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014–1021.
4. Galvani M, Ferrini D and Ottani F. Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Eur J Heart Fail 2004; 6: 327–333.
5. James SK, Lindahl B, Siegbahn A, et al. N-terminal probrain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003; 108: 275–281.
6. Omland T, de Lemos JA, Morrow DA, et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol 2002; 89: 463–465.
7. Eggers KM, Lagerqvist B, Venge P, et al. Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol 2009; 54: 357–364.
8. Eren NK, Ertas F, Yuksek U, et al. Additive prognostic value of NT-proBNP over TIMI risk score in intermediate-risk patients with acute coronary syndrome. Turk Kardiyol Dern Ars 2009; 37: 1–8.
9. Jarai R, Iordanova N, Jarai F, et al. Prediction of clinical outcome in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) using the TIMI risk score extended by N-terminal pro-brain natriuretic peptide levels. Wien Klin Wochenschr 2007; 119: 626–632.
10. Ang DS, Wei L, Kao MP, et al. A comparison between B-type natriuretic peptide, global registry of acute coronary events (GRACE) score and their combination in ACS risk stratification. Heart 2009; 95: 1836–1842.
11. Beygui F, Silvain J, Pena A, et al. Usefulness of biomarker strategy to improve GRACE score's prediction performance in patients with non-ST-segment elevation acute coronary syndrome and low event rates. Am J Cardiol 2010; 106: 650–658.
12. Meune C, Drexler B, Haaf P, et al. The GRACE score's performance in predicting in-hospital and 1-year outcome in the era of high-sensitivity cardiac troponin assays and B-type natriuretic peptide. Heart 2011; 97: 1479–1483.
13. Pencina MJ, D'Agostino RB and Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157–172.
14. Sanchis J, Avanzas P, Bayes-Genis A, et al. [New statistical methods in cardiovascular research]. Rev Esp Cardiol 2011; 64: 499–500.
15. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol 2007; 50: e1–e157.
16. Sacks DB, Arnold M, Bakris GL, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2011; 34: e61–e99.
17. Donders A, Vanderheijden G, Stijnen T, et al. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 2006; 59: 1087–1091.
18. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000; 284: 835–842.
19. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the Global Registry of Acute Coronary Events. Arch Intern Med 2003; 163: 2345–2353.
20. Ambler G, Brady AR and Royston P. Simplifying a prognostic model: a simulation study based on clinical data. Stat Med 2002; 21: 3803–3822.
21. Moreau T, O'Quigley J, Lellouch J, et al. Shoenfeld's approach for testing the proportional hazards assumption. Biometrika 1986; 73: 513–515.
22. Newson RB. Comparing the predictive power of survival models using Harrell's c or Somers' D. Stata J 2010; 10: 339–358.
23. Steyerberg EW, Harrell FE Jr, Borsboom GJ, et al. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001; 54: 774–781.
24. Pencina MJ, D'Agostino RB and Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30: 11–21.
25. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004; 291: 2727–2733.
26. Jernberg T, Stridsberg M, Venge P, et al. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002; 40: 437–445.
27. Morrow DA, de Lemos JA, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003; 41: 1264–1272.
28. Altman DG and Royston P. The cost of dichotomising continuous variables. BMJ 2006; 332: 1080.
29. Sanchis J, Nunez J, Bodi V, et al. Influence of Comorbid Conditions on One-Year Outcomes in Non-ST-Segment Elevation Acute Coronary Syndrome. Mayo Clin Proc 2011; 86: 291–296.
30. Bagnall AJ, Goodman SG, Fox KA, et al. Influence of age on use of cardiac catheterization and associated outcomes in patients with non-ST-elevation acute coronary syndromes. Am J Cardiol 2009; 103: 1530–1536.
31. Sabatine MS, Morrow DA, Cannon CP, et al. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy – Thrombolysis in Myocardial Infarction 18 trial) substudy. J Am Coll Cardiol 2002; 40: 1761–1768.
32. Fox KA, Clayton TC, Damman P, et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a metaanalysis of individual patient data. J Am Coll Cardiol 2010; 55: 2435–2445.
33. Fox KA, Poole-Wilson P, Clayton TC, et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet 2005; 366: 914–920.
34. Filipiak KJ, Koltowski L, Grabowski M, et al. Prospective comparison of the 5 most popular risk scores in clinical use for unselected patients with acute coronary syndrome. Circ J 2010; 75: 167–173.
35. Rawlings C, Oglesby K, Turner J, et al. Comparison of two clinical scoring systems in risk stratification of non-ST elevation acute coronary syndrome patients in predicting 30-day outcomes. Emerg Med J 2012; 29: 40–42.
36. Sinclair H, Paterson M, Walker S, et al. Predicting outcome in patients with acute coronary syndrome: evaluation of B-type natriuretic peptide and the global registry of acute coronary events (GRACE) risk score. Scot Med J 2007; 52: 8–13.
37. Khan SQ, Narayan H, Ng KH, et al. N-terminal pro-B-type natriuretic peptide complements the GRACE risk score in predicting early and late mortality following acute coronary syndrome. Clin Sci (Lond) 2009; 117: 31–39.
38. Lindahl B, Lindback J, Jernberg T, et al. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol 2005; 45: 533–541.
39. Talwar S, Squire IB, Downie PF, et al. Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Eur Heart J 2000; 21: 1514–1521.
40. White M, Rouleau JL, Hall C, et al. Changes in vasoconstrictive hormones, natriuretic peptides, and left ventricular remodeling soon after anterior myocardial infarction. Am Heart J 2001; 142: 1056–1064.
41. Jernberg T, James S, Lindahl B, et al. Natriuretic peptides in unstable coronary artery disease. Eur Heart J 2004; 25: 1486–1493.